Cargando…

CAR-T cells targeting CD38 and LMP1 exhibit robust antitumour activity against NK/T cell lymphoma

BACKGROUND: Natural killer/T cell lymphoma (NKTCL) is an aggressive lymphoma with a poor prognosis. Chimeric antigen receptor-transduced T (CAR-T) cell therapy has become a promising immunotherapeutic strategy against haematologic malignancies. METHODS: In this study, four CAR-T cell lines (CD38-CAR...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Hongwen, Song, Wenting, Wu, Jiazhuo, Shi, Zhuangzhuang, Gao, Yuyang, Li, Jiwei, Han, Lijuan, Zhang, Jianxiang, Li, Zhaoming, Li, Yong, Zhang, Mingzhi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10470138/ https://www.ncbi.nlm.nih.gov/pubmed/37649020 http://dx.doi.org/10.1186/s12916-023-03040-0

Ejemplares similares

A second‐generation CD38‐CAR‐T cell for the treatment of multiple myeloma
por: Li, Hongwen, et al.
Publicado: (2023)

P1378: CAR-T CELLS TARGETING CD38 AND LMP1 EXHIBIT ROBUST ANTI-TUMOR ACTIVITY AGAINST NK/T-CELL LYMPHOMA
por: Hongwen, LI, et al.
Publicado: (2023)

Preclinical and clinical studies of CAR-NK-cell therapies for malignancies
por: Li, Hongwen, et al.
Publicado: (2022)

PARP inhibitor exerts an anti-tumor effect via LMO2 and synergizes with cisplatin in natural killer/T cell lymphoma
por: Wu, Jiazhuo, et al.
Publicado: (2023)

Emerging roles of the gut microbiota in cancer immunotherapy
por: Shi, Zhuangzhuang, et al.
Publicado: (2023)

LMP1 and LMP2A are potential prognostic markers of extranodal NK/T-cell lymphoma, nasal type (ENKTL)
por: Mao, Yuan, et al.
Publicado: (2012)

Characteristics and Clinical Implications of the Nasal Microbiota in Extranodal NK/T-Cell Lymphoma, Nasal Type
por: Shi, Zhuangzhuang, et al.
Publicado: (2021)

T-cell dysfunction in natural killer/T-cell lymphoma
por: Feng, Xiaoyan, et al.
Publicado: (2023)

Potential strategies against resistance to CAR T-cell therapy in haematological malignancies
por: Cai, Qing, et al.
Publicado: (2020)

PB2277: PROGNOSTIC SIGNIFICANCE OF SERUM MONOCLONAL PROTEINS BASED ON IMMUNOFIXATION ELECTROPHORESIS IN B CELL NON-HODGKIN LYMPHOMA
por: Gao, Yuyang, et al.
Publicado: (2023)

CAR exosomes derived from effector CAR-T cells have potent antitumour effects and low toxicity
por: Fu, Wenyan, et al.
Publicado: (2019)

ORP8 induces apoptosis by releasing cytochrome c from mitochondria in non-small cell lung cancer
por: Li, Jiwei, et al.
Publicado: (2020)

Genetic variability in LMP2 and LMP7 is associated with the risk of esophageal squamous cell carcinoma in the Kazakh population but is not associated with HPV infection
por: Yang, Lan, et al.
Publicado: (2017)

Long-term Outcome of Extranodal NK/T Cell Lymphoma Patients Treated With Postremission Therapy Using EBV LMP1 and LMP2a-specific CTLs
por: Cho, Seok-Goo, et al.
Publicado: (2015)

CDC27 Promotes Tumor Progression and Affects PD-L1 Expression in T-Cell Lymphoblastic Lymphoma
por: Song, Yue, et al.
Publicado: (2020)

Corrigendum: CDC27 Promotes Tumor Progression and Affects PD-L1 Expression in T-Cell Lymphoblastic Lymphoma
por: Song, Yue, et al.
Publicado: (2021)

CD38‐Specific CAR Integrated into CD38 Locus Driven by Different Promoters Causes Distinct Antitumor Activities of T and NK Cells
por: Liao, Chan, et al.
Publicado: (2023)

Midazolam exhibits antitumour and enhances the efficiency of Anti-PD-1 immunotherapy in hepatocellular carcinoma
por: Kang, Junwei, et al.
Publicado: (2022)

Overexpression of S100A9 in tumor stroma contribute to immune evasion of NK/T cell lymphoma and predict poor response rate
por: Zhou, Zhiyuan, et al.
Publicado: (2021)

CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy
por: Pan, Kevin, et al.
Publicado: (2022)

Co-Inhibition of the Immunoproteasome Subunits LMP2 and LMP7 Ameliorates Immune Thrombocytopenia
por: Du, Sheng-hong, et al.
Publicado: (2021)

Current Progress of CAR-NK Therapy in Cancer Treatment
por: Pang, Zhaojun, et al.
Publicado: (2022)

PB2388: ALTERATIONS OF THE GUT MICROBIOTA AS A NON-INVASIVE DIAGNOSTIC BIOMARKER FOR NATURAL KILLER/T-CELL LYMPHOMA
por: Shi, Zhuangzhuang, et al.
Publicado: (2023)

Horses for Courses in the Era of CARs: Advancing CAR T and CAR NK Cell Therapies
por: Kulemzin, Sergey, et al.
Publicado: (2021)

LMP1‐positive extracellular vesicles promote radioresistance in nasopharyngeal carcinoma cells through P38 MAPK signaling
por: Zhang, Zhibao, et al.
Publicado: (2019)

Combined treatment with anti‐PSMA CAR NK‐92 cell and anti‐PD‐L1 monoclonal antibody enhances the antitumour efficacy against castration‐resistant prostate cancer
por: Wang, Fangming, et al.
Publicado: (2022)

From CAR-T Cells to CAR-NK Cells: A Developing Immunotherapy Method for Hematological Malignancies
por: Lu, Hui, et al.
Publicado: (2021)

Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy
por: Gong, Ying, et al.
Publicado: (2021)

Biomarkers as targets for CAR-T/NK cell therapy in AML
por: Shao, Ruonan, et al.
Publicado: (2023)

Low-dose decitabine priming endows CAR T cells with enhanced and persistent antitumour potential via epigenetic reprogramming
por: Wang, Yao, et al.
Publicado: (2021)

Cytokines induced memory-like NK cells engineered to express CD19 CAR exhibit enhanced responses against B cell malignancies
por: He, Bailin, et al.
Publicado: (2023)

CAR‐NK cells: the next wave of cellular therapy for cancer
por: Daher, May, et al.
Publicado: (2021)

An Overview of Antitumour Activity of Polysaccharides
por: Jin, Hongzhen, et al.
Publicado: (2022)

The association between the genetic polymorphisms of LMP2/LMP7 and the outcomes of HCV infection among drug users()
por: Cui, Qian, et al.
Publicado: (2010)

Advancements in CAR-NK therapy: lessons to be learned from CAR-T therapy
por: Kilgour, Marisa K., et al.
Publicado: (2023)

P1229: PARP INHIBITORS ARE EFFECTIVE IN NATURAL KILLER/T CELL LYMPHOMA VIA THE EXPRESSION OF LMO2
por: Wu, Jiazhuo, et al.
Publicado: (2023)

Importance of T, NK, CAR T and CAR NK Cell Metabolic Fitness for Effective Anti-Cancer Therapy: A Continuous Learning Process Allowing the Optimization of T, NK and CAR-Based Anti-Cancer Therapies
por: Krug, Adrien, et al.
Publicado: (2021)

Antitumour Antibiotics
por: Fox, B. W.
Publicado: (1979)

Engineering the next generation of CAR-NK immunotherapies
por: Biederstädt, Alexander, et al.
Publicado: (2021)

CAR-NK Cells in the Treatment of Solid Tumors
por: Wrona, Ewa, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_btugfk35psj25oiutl7kcf0o5s